Biofrontera Inc. (BFRI)

1,9600 +0,1100 (+5,95%) Börsenschluss: 04:00PM EDT

Biofrontera Inc.

120 Presidential Way
Suite 330
Woburn, MA 01801
United States
781-245-1325
https://www.biofrontera-us.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 83

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Hermann Luebbert Ph.D.	CEO, President & Executive Chairman	733,23k	N/A	1956
Mr. Eugene Frederick Leffler III	Chief Financial Officer	378,58k	N/A	1985
Ms. Erica F. Gates CPA, M.B.A.	Senior Director of Finance & Principal Accounting Officer	N/A	N/A	N/A
Mr. Jon Lyons M.B.A., Ph.D.	Vice President of Scientific & Medical Affairs	N/A	N/A	N/A
Ms. Alycia Torres	Vice President of Administration	N/A	N/A	N/A
Mr. Daniel Hakansson J.D.	General Counsel & Head of Compliance	N/A	N/A	N/A
Ms. Samantha Widdicombe	Senior Director of Strategic Accounts & Communications	N/A	N/A	N/A
Mr. Mark Baldyga	Vice President of Sales & Marketing	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Corporate Governance

Biofrontera Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.